During a live event, Caitlin Costello, MD, discussed the AQUILA trial and its potential impact on treatment for high-risk smoldering myeloma.

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering ...

In 2014, the International Myeloma Working Group (IMWG) updated the diagnostic criteria for multiple myeloma – a change that has had a profound effect on the concept of early treatment of patients ...

Chimeric antigen receptor T-cell therapy conferred sustained benefit to individuals with high-risk smoldering multiple myeloma, according to phase 2 trial results. All patients who received a single ...

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained ...

Darzalex Faspro significantly reduced disease progression risk in high-risk smoldering multiple myeloma, with a 51% reduction compared to active monitoring. The AQUILA study showed a median ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk ...

It’s a reasonable hope, given the results of that trial, which researchers presented at the American Association for Cancer ...

TORONTO -- Linvoseltamab (Lynozyfic) appeared effective in patients with high-risk smoldering multiple myeloma (HR-SMM), according to preliminary phase II trial data. With a median follow-up of 3.9 ...

What Is Darzalex Faspro, and Why Does It Matter? Darzalex Faspro is a medicine used to treat adults with multiple myeloma, a type of blood cancer, and amyloidosis, a rare condition where abnormal ...

Dana-Farber Cancer Institute investigators have developed an online, easy-to-use tool that more accurately predicts when a precursor blood condition called smoldering multiple myeloma is likely to ...